Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00669
|
|||||
| Drug Name |
Clofazimine
|
|||||
| Synonyms |
(3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine; 3-(p-Chloranilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin; 3-(p-Chloranilino)-10-(p-chlorphenyl)-2,10-dihydro-2-(isopropylimino)-phenazin [German]; 3-(p-Chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; B 663; B 663 (Pharmaceutical); B 663 (VAN); B 663, pharmaceutical; B-663; B. 663; CFZ; Chlofazimine; Clofazimina; Clofazimina [INN-Spanish]; Clofazimine (JAN/USP/INN); Clofazimine [USAN:INN:BAN]; Clofaziminum; Clofaziminum [INN-Latin]; G 30320; G-30,320; G-30320; Lampren; Lamprene; Lamprene (TN); Liposome-encapsulated clofazimine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(1-methylethyl)imino)-2-phenazinamine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-(isopropylimino)phenazin-2-amine; N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-[(1-methylethyl)imino]-2-phenazinamine; N,5-bis(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine; N,5-bis(4-chlorophenyl)-3-propan-2-yliminophenazin-2-amine; SMP2_000339
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Leprosy [ICD11:1B20] | Approved | [1] | |||
| Therapeutic Class |
Antiinflammatory Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H22Cl2N4
|
|||||
| Canonical SMILES |
CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
|
|||||
| InChI |
InChI=1S/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3
|
|||||
| InChIKey |
WDQPAMHFFCXSNU-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 2030-63-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 473.4 | Topological Polar Surface Area | 40 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
7.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321645
,103400985
,103755939
,103914133
,104153270
,104301631
,11112506
,11466404
,11467524
,11486188
,118816613
,121269827
,121363168
,14761008
,15356285
,24714740
,24893114
,29221949
,32963436
,426821
,4302579
,46386952
,46508174
,47275676
,47349472
,47499671
,47795160
,48243512
,48415799
,49681815
,49698463
,50004010
,50100467
,50124245
,50376246
,56314325
,57321463
,602744
,627688
,7847344
,7978968
,8151803
,855829
,9132
,92125497
,92308020
,92308564
,93167165
,93619701
,96079551
|
|||||
| ChEBI ID |
CHEBI:3749
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Clofazimine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy. J Antimicrob Chemother. 2016 Jan;71(1):17-26. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.